Developmental Funds support strategic priorities of the Duke Cancer Institute by providing resources for new investigators, pilot projects, and development or application of new technologies. All Cancer Center members are eligible to apply for these funds and all funding decisions are made after formal peer review by the DCI Scientific Review Committee (or the Shared Resource Oversight Committee for new technologies for Shared Resources). The recruiting funds are made available at any time through the year to maintain optimal flexibility in faculty recruitment. These funds are used to help support high-priority, newly recruited DCI faculty investigators and represent an important component of their institutional start-up funds. Pilot project applications are formally solicited via Requests for Applications twice each year. All applications are reviewed by the Scientific Review Committee for scientific quality and impact as well as alignment with DCI priorities. The two co-chairs of the Scientific Review Committee, Drs. Chao and Counter, and the Chair of the Shared Resource Oversight Committee, Dr. Dewhirst, are members of the DCI Steering and Executive Committees, the former committee specifically charged with strategic oversight of the DCI; thus, Developmental Funds applications are reviewed with full consideration of DCI priorities. The Review Committee makes funding recommendations with final funding approval by the DCI Executive Director. One annual round of project Requests for Applications specifically solicits applications for innovative pilot projects and a second annual round specifically prioritizes inter-programmatic, intra-programmatic, and/or translational projects. Projects that would facilitate subsequent submission of multi-investigator grants (SPORES, Program Projects, etc.) are specifically encouraged. Typically, projects request approximately $50,000 per year and up to two years of support can be provided, though the second year of funding is dependent on approval of a second year of funding by the Scientific Review Committee which makes a determination of adequate progress during the first year of support by review of a formal progress report. During the funding period to date, $2M of CCSG support was distributed by this competitive application process to support the activities of more than 25 DCI investigators and over 40 pilot projects. Investigators receiving this support spanned all DCI Research Programs. In addition to the CCSG pilot funding support, these funds were supplemented by matching DCI funds and sometimes other sources to further leverage the CCSG support and provide a larger amount and broader distribution of support for these high priority activities. These investments resulted in approximately $41.5M of subsequent peer-reviewed and foundation support for DCI investigators. During the next funding period, plans are to continue to support new investigators, innovative high-priority pilot projects, and development or application of new technologies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications